TW200503666A - Treatment of type 1 diabetes with pde5 inhibitors - Google Patents
Treatment of type 1 diabetes with pde5 inhibitorsInfo
- Publication number
- TW200503666A TW200503666A TW093107099A TW93107099A TW200503666A TW 200503666 A TW200503666 A TW 200503666A TW 093107099 A TW093107099 A TW 093107099A TW 93107099 A TW93107099 A TW 93107099A TW 200503666 A TW200503666 A TW 200503666A
- Authority
- TW
- Taiwan
- Prior art keywords
- diabetes
- type
- treatment
- pde5 inhibitors
- substantial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45527703P | 2003-03-17 | 2003-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200503666A true TW200503666A (en) | 2005-02-01 |
Family
ID=33029981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW093107099A TW200503666A (en) | 2003-03-17 | 2004-03-17 | Treatment of type 1 diabetes with pde5 inhibitors |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1605925A1 (en) |
JP (1) | JP2006520777A (en) |
BR (1) | BRPI0408500A (en) |
CA (1) | CA2519357A1 (en) |
MX (1) | MXPA05009242A (en) |
TW (1) | TW200503666A (en) |
WO (1) | WO2004082667A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005235306B2 (en) * | 2004-04-19 | 2008-08-21 | Loma Linda University | Composition and method of decreasing renal ischemic damage |
EP1909793A2 (en) * | 2005-07-15 | 2008-04-16 | Proxomed Medizintechnik GmbH | Use of phosphodiesterase type 5 inhibitors for the prevention and treatment of diseases or health disorders and dispensing system for said inhibitors |
CA2617805A1 (en) * | 2005-08-04 | 2007-02-15 | Transform Pharmaceuticals, Inc. | Novel formulations comprising fenofibrate and a statin, and related methods of treatment |
EP2063890A1 (en) | 2006-09-07 | 2009-06-03 | Nycomed GmbH | Combination treatment for diabetes mellitus |
ES2465216T3 (en) | 2007-06-04 | 2014-06-05 | Ben Gurion University Of The Negev Research And Development Authority | Triaryl compounds and compositions comprising the same |
US9943517B2 (en) * | 2012-11-13 | 2018-04-17 | Nusirt Sciences, Inc. | Compositions and methods for increasing energy metabolism |
WO2014105655A1 (en) | 2012-12-24 | 2014-07-03 | Neurogastrx, Inc. | Methods for treating gi tract disorders |
CR20160207A (en) | 2013-11-05 | 2016-08-10 | Ben Gurion Univ Of The Negev Res And Dev Authority | COMPOUNDS FOR THE TREATMENT OF DIABETES AND COMPLICATIONS THAT COME FROM THE SAME DISEASE |
WO2015200369A1 (en) | 2014-06-24 | 2015-12-30 | Neurogastrx, Inc. | Prodrugs of metopimazine |
MX2017016930A (en) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Method of treatment of diabetic foot ulcers. |
US10836757B1 (en) | 2020-04-02 | 2020-11-17 | Neurogastrx, Inc. | Polymorphic forms of metopimazine |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2346937A1 (en) * | 1998-10-15 | 2000-04-27 | Per O. G. Arkhammar | Specific therapeutic interventions obtained by interference with redistribution and/or targeting |
KR100353014B1 (en) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | Pyrazolopyrimidinone derivatives for the treatment of impotence |
DE19944161A1 (en) * | 1999-09-15 | 2001-03-22 | Bayer Ag | New combination for the treatment of sexual dysfunction |
GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
EP1303279A1 (en) * | 2000-06-30 | 2003-04-23 | Ralph E. Wood | Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
KR20030023747A (en) * | 2000-08-11 | 2003-03-19 | 화이자 인코포레이티드 | Treatment of the insulin resistance syndrome |
WO2002060422A2 (en) * | 2001-02-02 | 2002-08-08 | Pfizer Limited | Treatment of diabetes mellitus using vardenafil |
GB0106631D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
ES2241994T3 (en) * | 2001-03-16 | 2005-11-01 | Pfizer Inc. | PIRAZOLO COMPOUNDS (4,3-D) PYRIMIDINONE AS GMPC INHIBITORS. |
US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
-
2004
- 2004-03-04 JP JP2006506327A patent/JP2006520777A/en active Pending
- 2004-03-04 CA CA002519357A patent/CA2519357A1/en not_active Abandoned
- 2004-03-04 BR BRPI0408500-0A patent/BRPI0408500A/en not_active Application Discontinuation
- 2004-03-04 MX MXPA05009242A patent/MXPA05009242A/en not_active Application Discontinuation
- 2004-03-04 EP EP04717183A patent/EP1605925A1/en not_active Withdrawn
- 2004-03-04 WO PCT/IB2004/000696 patent/WO2004082667A1/en not_active Application Discontinuation
- 2004-03-17 TW TW093107099A patent/TW200503666A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MXPA05009242A (en) | 2006-04-18 |
WO2004082667A1 (en) | 2004-09-30 |
EP1605925A1 (en) | 2005-12-21 |
BRPI0408500A (en) | 2006-03-07 |
CA2519357A1 (en) | 2004-09-30 |
JP2006520777A (en) | 2006-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
HK1080459A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
AU2003268144A1 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
IN2005KO00312A (en) | ||
HK1086186A1 (en) | Use of spongosine (2-methoxyadenosein) for preparing pharmaceutical for the treatment of pain | |
TW200639159A (en) | Treatment of pain | |
WO2004103297A3 (en) | Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis | |
WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
TW200616644A (en) | Medicine for prevention or treatment of diabetes | |
AU4258101A (en) | Combination therapies with vascular damaging activity | |
WO2003092606A3 (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
PT1656131E (en) | Use of betaine for treating intermittent claudication | |
WO2004006849A3 (en) | Combinations of drugs for the treatment of neoplasms | |
TW200503676A (en) | Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | |
EP1695969A4 (en) | Alpha-amino acid derivatives and use thereof as medicines | |
TW200603792A (en) | Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors | |
WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
TW200642688A (en) | New use of PDE7 inhibitors | |
MXPA05004920A (en) | Combination comprising a cdk inhibitor and cisplatin. | |
GB0313386D0 (en) | Treatment of disease | |
TW200610524A (en) | Medicine for prevention or treatment of diabetes | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
TW200608965A (en) | Medicine for prevention or treatment of diabetes |